CGRP Breakthroughs: New Migraine Treatments and Future Hopes
- MigraineMind
- Nov 27, 2025
- 1 min read
Research Summary
The study "CGRP and Migraine: Real World Insights and Future Therapeutic Directions" published in the Annual Review of Medicine highlights the successful translation of calcitonin gene-related peptide (CGRP) targeting from research to clinical application in treating migraines. Eight monoclonal antibodies and small-molecule receptor antagonists have been approved by the FDA, offering new options for acute and preventive migraine treatment. The review examines evolving real-world data, confirming the drugs' safety while acknowledging some adverse effects. It also explores potential future uses of CGRP inhibitors for other disorders and anticipates advancements in combinatorial and neuropeptide-based treatments inspired by CGRP research.
Study Details
👥 Research Team: Russo AF, Kaiser EA
📚 Published In: Annu Rev Med
📅 Publication Date: 2025 Nov 26
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.